ESR1 and neoplasm: We utilize the monoclonal pan-ER (SP-1, C-terminal domain) antibody–tested in BCa cell lines [27, 28], mouse models [29], patient tumor ER-α status [30, 31]–as an immunoreagent to detect the frequency and expression levels of ER-α isoforms.